SPIRIT II Results Highlight Strength of Boston Scientific Stent Portfolio

- International Data Suggests Low Revascularization Rates for Both TAXUS(TM) Stent and PROMUS(TM) (XIENCE(TM) V) Stent

Boston Scientific Corporation (NYSE: BSX) today welcomed the results of Abbott's SPIRIT II clinical trial, which reaffirmed the safety and efficacy of the market-leading TAXUS(TM) stent, and provided promising data on Abbott's XIENCE(TM) V everolimus-eluting coronary stent system (which will be marketed by Boston Scientific as the PROMUS(TM) stent[1]). Designed as a non-

"SPIRIT II adds to the extensive body of clinical evidence from randomized trials that reinforce the excellent safety and efficacy of the TAXUS stent system, and provides solid traction for growth of the PROMUS stent," said Jeff Goodman, President of Boston Scientific International. "The TAXUS stent continues to demonstrate exceptional deliverability and the proven clinical

After presenting the data, Prof. Patrick Serruys, the principal investigator of the trial, stated, "While PROMUS met the trial's primary non-inferiority endpoint of in-stent late loss, larger confirmatory trials will be required to validate the safety and effectiveness shown to date."

SPIRIT II is a randomized, multi-center, non-inferiority trial designed to evaluate the XIENCE V everolimus-eluting coronary stent system, manufactured and sold by Abbott, and marketed by Boston Scientific as the PROMUS stent, against the TAXUS(TM) Express2(TM) paclitaxel-eluting coronary stent system in the treatment of coronary artery disease. The primary endpoint was in-stent late loss at six months. The study reported an in-stent late loss of 0.11mm for the XIENCE V Stent, and 0.36mm for the TAXUS stent, which is consistent with TAXUS stent results in previous trials. Secondary endpoints included ischemia-driven target lesion revascularization (TLR), which was 1.8% for the XIENCE V stent and 3.9% for the TAXUS stent.

About Boston Scientific

Boston Scientific is a worldwide developer, manufacturer and marketer of medical devices whose products are used in a broad range of interventional medical specialties. For more information, please visit: www.bostonscientific.com or

This press release contains forward-looking statements. The Company wishes to caution the reader of this press release that actual results may differ from those discussed in the forward-looking statements and may be adversely affected by, among other things, operational improvements, and other factors described in the Company's filings with the Securities and Exchange Commission.

[1]PROMUS(TM) stent: CE Mark pending. Not available for sale in the European Economic Area. Not for use or distribution in the United States.

SOURCE Boston Scientific Corporation

CONTACT: Geraldine Varoqui,

Boston Scientific PR Manager International,

Tel: +49-2102-489-461,

[email protected] , or

Tracy Paul,

BSC press office,

Tel: +44-20-7413-3101, [email protected]

Web site: http://www.bostonscientific.com

http://www.publicaster.com/info/bostonscientific/esc2006 /

--Distributed by AsiaNet ( www.asianetnews.net )--

• ข่าวBoston Scientific
• ข่าวo:asn
• ข่าวen
• ข่าวo:in